Distinct Chronic Post-Viral Lung Diseases upon Infection with Influenza or Parainfluenza Viruses Differentially Impact Superinfection Outcome

Keyphrases

• Appropriate Therapy 33%
• Asthma 100%
• Chronic Lung Disease 66%
• Chronic Obstructive Pulmonary Disease 100%
• Composition Profile 33%
• Differential Effects 33%
• Disease Exacerbation 33%
• Early Infection 33%
• Human Lung Disease 33%
• Inflammatory Profile 33%
• Influenza A 33%
• Influenza Virus 100%
• Lung 33%
• Lung Disease 100%
• Parainfluenza Virus 100%
• Pathologic 33%
• Pathological Findings 33%
• Post-viral 100%
• Pregenomic RNA (pgRNA) 33%
• Primary Infection 33%
• Respiratory Syncytial Virus 33%
• Sendai Virus 100%
• Superinfection 100%
• Susceptibility to Disease 33%
• Viral 33%
• Viral Challenge 66%
• Viral Infection 66%
• Viral Model 33%
• Virus Infection 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Asthma 50%
• Chronic Lung Disease 33%
• Chronic Obstructive Lung Disease 50%
• Disease Exacerbation 16%
• Diseases 100%
• Human Respiratory Syncytial Virus 16%
• Infection 100%
• Influenza A 16%
• Influenza A Virus 16%
• Influenza Virus 100%
• Lung Disease 16%
• Paramyxovirinae 100%
• Primary Infection 16%
• Sendai Virus 33%
• Sendai Virus Infection 16%
• Superinfection 100%
• Virus Infection 33%
• Virus RNA 16%

Immunology and Microbiology

• Asthma 100%
• Human Respiratory Syncytial Virus 33%
• Influenza 33%
• Influenza Virus 100%
• Influenzavirus A 33%
• Paramyxovirinae 100%
• Sendai Virus 100%
• Superinfection 100%
• Viral Disease 100%